Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

被引：0

作者：

Eliazar Sabater

Armando López-Guillermo

Antonio Rueda

Antonio Salar

Itziar Oyagüez

Juan Manuel Collar

机构：

[1] Pharmacoeconomics and Outcomes Research Iberia,Haematology Department

[2] Hospital Clinic,Oncology Department

[3] Hospital Costa del Sol,Haematology Department

[4] Hospital del Mar,Medical Department

[5] Mundipharma Pharmaceuticals,undefined

来源：

Applied Health Economics and Health Policy | 2016年 / 14卷

关键词：

Follicular Lymphoma; Bendamustine; Bayesian Information Criterion; Progression State; Spanish National Health System;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：465 / 477

页数：12

共 249 条

[31]

Krivacic S(undefined)undefined undefined undefined undefined-undefined

[32]

LaCasce AS(undefined)undefined undefined undefined undefined-undefined

[33]

Nademanee A(undefined)undefined undefined undefined undefined-undefined

[34]

Porcu P(undefined)undefined undefined undefined undefined-undefined

[35]

Press O(undefined)undefined undefined undefined undefined-undefined

[36]

Rabinovitch R(undefined)undefined undefined undefined undefined-undefined

[37]

Reddy N(undefined)undefined undefined undefined undefined-undefined

[38]

Reid E(undefined)undefined undefined undefined undefined-undefined

[39]

Sokol L(undefined)undefined undefined undefined undefined-undefined

[40]

Swinnen LJ(undefined)undefined undefined undefined undefined-undefined